Copyright: ©Author(s) 2026.
World J Hepatol. Oct 27, 2026; 18(10): 123267
Published online Oct 27, 2026. doi: 10.4254/wjh.123267
Published online Oct 27, 2026. doi: 10.4254/wjh.123267
Table 3 Comparison of laboratory findings between patients with hyperthyroidism-induced liver injury with antithyroid drug exposure and those without antithyroid drug exposure, n (%)/median (interquartile range)
| Items | Total (n = 140) | ATD (-) (n = 40) | ATD (+) (n = 100) | P value |
| Laboratory findings pre-treatment | ||||
| Blood routine | ||||
| WBC (× 109/L) | 6.21 (5.42, 8.17) | 6.45 (5.61, 8.21) | 6.03 (5.38, 8.02) | 0.570 |
| RBC (× 1012/L) | 3.83 (2.94, 4.32) | 3.68 (2.92, 4.21) | 3.95 (2.98, 4.54) | 0.161 |
| PLT (× 109/L) | 142.3 (106.5, 204.8) | 164.8 (114.4, 210.0) | 136.0 (92.3, 190.4) | 0.172 |
| HGB (g/L) | 114.3 (93.0, 130.9) | 111.9 (92.3, 126.6) | 118.1 (95.1, 132.2) | 0.166 |
| NEUT (× 109/L) | 4.91 (2.19, 7.56) | 4.72 (2.12, 7.33) | 5.15 (2.23, 7.68) | 0.590 |
| Hepatic function | ||||
| ALT (μ/L) | 284.9 (128.6, 315.5) | 284.4 (128.3, 310.0) | 286.1 (130.4, 318.4) | 0.983 |
| AST (μ/L) | 231.7 (105.3, 283.6) | 241.5 (109.2, 294.0) | 224.6 (102.6, 281.3) | 0.779 |
| TBIL (μmol/L) | 272.3 (86.1, 405.4) | 280.9 (85.6, 451.1) | 269.9 (97.8, 373.9) | 0.810 |
| DBIL (μmol/L) | 196.5 (55.8, 336.2) | 206.2 (50.6, 368.6) | 193.2 (68.1, 260.8) | 0.705 |
| TP (g/L) | 61.92 (48.8, 76.1) | 62.47 (49.3, 76.3) | 61.54 (48.4, 75.9) | 0.630 |
| ALB (g/L) | 28.22 (21.8, 34.6) | 27.81 (21.6, 34.3) | 28.85 (22.7, 34.9) | 0.246 |
| GGT (U/L) | 83.28 (68.36, 105.5) | 74.11 (61.42, 96.32) | 98.34 (71.38, 118.0) | 0.1268 |
| ALP (U/L) | 162.4 (113.6, 214.4) | 159.5 (109.2, 208.3) | 173.0 (119.2, 226.4) | 0.4333 |
| Coagulation function | ||||
| PT (seconds) | 18.87 (14.92, 24.16) | 18.67 (14.23, 23.62) | 19.05 (15.33, 25.13) | 0.781 |
| APTT (seconds) | 48.87 (38.02, 61.24) | 49.91 (38.36, 62.42) | 48.42 (37.92, 60.67) | 0.631 |
| INR | 1.62 (1.22, 2.15) | 1.61 (1.21, 2.14) | 1.63 (1.23, 2.16) | 0.906 |
| Thyroid function | ||||
| FT3 (pmol/L) | 10.20 (5.12, 13.62) | 8.71 (3.24, 13.58) | 11.63 (6.50, 14.13) | 0.077 |
| FT4 (pmol/L) | 19.41 (8.12, 24.55) | 17.02 (3.76, 24.00) | 21.72 (10.76, 25.00) | 0.067 |
| TT3 (nmol/L) | 3.50 (2.47, 4.36) | 3.22 (2.30, 4.20) | 3.77 (2.89, 4.56) | 0.114 |
| TT4 (nmol/L) | 127.2 (96.5, 150.3) | 122.8 (83.5, 146.0) | 139.7 (110.0, 156.9) | 0.091 |
| TSH (μIU/mL) | 0.24 (0.01, 0.42) | 0.32 (0.01, 0.51) | 0.17 (0.01, 0.34) | 0.198 |
| TRAb (IU/mL) | 15.08 (8.16, 17.00) | 15.22 (7.80, 18.20) | 14.99 (9.10, 16.80) | 0.904 |
| TgAb (μ/mL) | 210.6 (29.1, 370.3) | 222.1 (34.1, 349.0) | 202.6 (27.9, 400.0) | 0.748 |
| A-TPO (μ/mL) | 501.2 (39.3, 913.6) | 533.7 (39.5, 990.0) | 477.9 (39.2, 880.0) | 0.5634 |
| Laboratory findings post-treatment | ||||
| Blood routine | ||||
| WBC (× 109/L) | 5.62 (3.67, 7.03) | 5.85 (3.38, 7.76) | 5.40 (4.01, 6.64) | 0.446 |
| RBC (× 1012/L) | 3.93 (3.10, 4.57) | 3.57 (2.71, 4.35) | 4.25 (3.64, 4.83) | 0.003 |
| PLT (× 109/L) | 180.0 (93.4, 269.3) | 155.7 (79.0, 209.0) | 218.2 (127.0, 312.0) | 0.021 |
| HGB (g/L) | 112.2 (96.0, 128.2) | 108.0 (87.0, 121.9) | 118.6 (104.0, 133.5) | 0.061 |
| NEUT (× 109/L) | 3.36 (2.01, 4.33) | 3.58 (1.87, 4.53) | 3.23 (2.18, 4.02) | 0.456 |
| Hepatic function | ||||
| ALT(μ/L) | 48.20 (29.0, 63.4) | 51.64 (27.0, 72.3) | 45.34 (31.0, 58.3) | 0.358 |
| AST (μ/L) | 56.18 (31.2, 70.8) | 59.73 (33.5, 72.8) | 54.25 (29.5, 69.8) | 0.558 |
| TBIL (μmol/L) | 94.0 (21.8, 121.3) | 117.6 (23.0, 139.5) | 70.18 (20.0, 107.3) | 0.025 |
| DBLI (μmol/L) | 71.69 (11.0, 95.2) | 90.81 (11.5, 123.6) | 53.43 (10.5, 75.2) | 0.033 |
| TP (g/L) | 66.18 (59.9, 73.4) | 64.36 (57.9, 70.2) | 69.03 (63.1, 77.0) | 0.024 |
| ALB (g/L) | 34.28 (31.0, 38.0) | 34.09 (30.4, 38.3) | 34.69 (32.2, 37.9) | 0.566 |
| GGT (U/L) | 72.17 (42.6, 83.0) | 85.11 (57.8, 90.0) | 59.14 (36.6, 66.0) | 0.039 |
| ALP (U/L) | 106.2 (75.0, 124.5) | 120.6 (87.0, 134.0) | 91.90 (65.0, 113.5) | 0.0005 |
| Coagulation function | ||||
| PT (seconds) | 14.64 (13.1, 15.3) | 15.90 (13.6, 17.6) | 13.91 (12.5, 15.3) | 0.007 |
| APTT (seconds) | 41.00 (36.2, 46.7) | 43.49 (36.0, 48.3) | 40.40 (36.5, 42.2) | 0.135 |
| INR | 1.21 (0.98, 1.31) | 1.34 (1.07, 1.48) | 1.12 (0.90, 1.28) | 0.017 |
| Thyroid function | ||||
| FT3 (pmol/L) | 6.35 (4.00, 9.21) | 7.13 (4.00, 11.00) | 5.49 (4.00, 6.46) | 0.035 |
| FT4 (pmol/L) | 7.12 (2.03, 12.30) | 8.90 (1.86, 16.12) | 6.09 (2.12, 9.00) | 0.033 |
| TT3 (nmol/L) | 2.49 (1.81, 3.02) | 2.58 (1.89, 3.12) | 2.42 (1.79, 2.93) | 0.472 |
| TT4 (nmol/L) | 64.12 (23.5, 82.1) | 71.82 (23.4, 91.0) | 55.53 (23.7, 78.0) | 0.023 |
| TSH (μIU/mL) | 1.02 (0.21, 1.54) | 0.52 (0.01, 0.74) | 1.53 (0.70, 2.40) | < 0.0001 |
| TRAb (IU/mL) | 8.37 (3.50, 10.04) | 11.43 (4.71, 15.82) | 5.15 (2.53, 7.01) | < 0.0001 |
| TgAb (μ/mL) | 140.6 (23.5, 260.3) | 183.9 (29.3, 336.0) | 109.1 (19.2, 155.3) | 0.071 |
| A-TPO (μ/mL) | 382.1 (42.5, 712.0) | 478.5 (56.0, 768.0) | 317.6 (39.5, 678.0) | 0.061 |
- Citation: Yu W, Dai ZS, Li YH, Li MP, Li J, Jiao KX, Ma J, Li Y. Proactive antithyroid therapy improves survival in hyperthyroidism-induced liver injury: A real-world cohort study. World J Hepatol 2026; 18(10): 123267
- URL: https://www.wjgnet.com/1948-5182/full/v18/i10/123267.htm
- DOI: https://dx.doi.org/10.4254/wjh.123267